(Q37380388)

20 August 2017

1 reference

title

Development of novel treatments for hepatitis C. (English)

1 reference

20 August 2017

2

Paul Klenerman

1 reference

20 August 2017

Daniel P Webster

1

1 reference

PubMed ID

19179226

20 August 2017

Jane Collier

series ordinal

3

1 reference

PubMed ID

19179226

20 August 2017

Katie J M Jeffery

series ordinal

4

1 reference

20 August 2017

1 February 2009

1 reference

Lancet Infectious Diseases

20 August 2017

1 reference

20 August 2017

9

1 reference

20 August 2017

108-117

1 reference

20 August 2017

2

1 reference

Viral hepatitis: new data on hepatitis C infection

20 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Epidemiology of hepatitis B and hepatitis B virus infection in United States children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Epidemiology of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Hepatitis C in Pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Caesarean section versus vaginal delivery for preventing mother to infant hepatitis C virus transmission

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Sexual transmission of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Epidemiology of viral hepatitis and HIV co-infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

HCV-HIV coinfection: simple messages from a complex disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Relation between HIV-1 and hepatitis C viral load in patients with hemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Nucleotide sequence and mutation rate of the H strain of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

A novel immunocompetent rat model of HCV infection and hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Engraftment and Development of Human T and B Cells in Mice After Bone Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Chronic infection with hepatitis B viruses and antiviral drug evaluation in uPA mice after liver repopulation with tupaia hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

New animal models for hepatitis C viral infection and pathogenesis studies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Cell entry of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Hepatitis C virus receptor expression in normal and diseased liver tissue

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

The CD81 Partner EWI-2wint Inhibits Hepatitis C Virus Entry

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Coordinated assembly of human translation initiation complexes by the hepatitis C virus internal ribosome entry site RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

The pathway of HCV IRES-mediated translation initiation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Structural biology of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

A second hepatitis C virus-encoded proteinase

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Novel insights into hepatitis C virus replication and persistence

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Selective binding of hepatitis C virus core protein to synthetic oligonucleotides corresponding to the 5' untranslated region of the viral genome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Analysis of successful immune responses in persons infected with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Adaptive immune responses in acute and chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Protective effect of HLA-B57 on HCV genotype 2 infection in a West African population

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

The epidemiology of hepatitis C infection in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

1 reference

7 January 2021

Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Projecting future complications of chronic hepatitis C in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Rising incidence of hepatocellular carcinoma in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Extrahepatic disease manifestations of HCV infection: some current issues

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Hepatitis C virus infection in patients with essential mixed cryoglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Membranoproliferative glomerulonephritis associated with hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Hepatitis C virus: virology, diagnosis and management of antiviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Selective inhibitors of hepatitis C virus replication

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Emerging strategies for pegylated interferon combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Rapid virologic response: a new milestone in the management of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

A short course of pegylated interferon-alpha in acute HCV hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Twelve-week treatment of acute hepatitis C virus with pegylated interferon- alpha -2b in injection drug users

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Recent development of therapeutics for chronic HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Inhibition of hepatitis C virus infection in cell culture by small interfering RNAs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Review article: novel therapeutic options for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

The hepatitis C virus life cycle as a target for new antiviral therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Phase 2 study of the combination of merimepodib with peginterferon-alpha2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Antivirals and antiviral strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

The interferon inducing pathways and the hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Non-nucleoside inhibitors of the HCV polymerase

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Therapeutic application of RNA interference for hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Induction of apoptosis by the dsRNA-dependent protein kinase (PKR): mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

Therapeutic strategies in the management of patients with chronic hepatitis B virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970020-9

7 January 2021

10.1016/S1473-3099(09)70020-9

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19179226